Press Releases

Date Title and Summary Additional Formats
Toggle Summary SAN DIEGO , Sept. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company Read All » View HTML
Toggle Summary TCR - CAR + iPSC-derived CD8αβ T Cells Induced Complete and Durable Responses In Vivo in Systemic Leukemia Model Cell-surface Markers, Gene Transcription Profile, and In Vivo Anti-tumor Activity of TCR - CAR + iPSC-derived CD8αβ T Cells Compared Favorably with Healthy-donor Peripheral Blood CAR T Read All » View HTML
Toggle Summary FT596+R Enrollment Ongoing in Multi-dose, Multi-cycle Cohorts for R/R BCL; Initiated Study Start-up for Investigation of FT596+R-CHOP in Newly-diagnosed Patients with Aggressive BCL FT516 RMAT Meeting Scheduled with FDA for 3Q22 to Discuss Registrational Pathways for R/R BCL First Patient Treated Read All » View HTML
Toggle Summary SAN DIEGO , July 25, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will Read All » View HTML
Toggle Summary SAN DIEGO , June 30, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Read All » View HTML
Toggle Summary ONO to Contribute Novel Binding Domains for a Second Solid Tumor Antigen to the Collaboration Expanded Partnership Enables Development of both CAR NK and CAR T-cell Collaboration Candidates for Solid Tumors SAN DIEGO , June 28, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All » View HTML
Toggle Summary SAN DIEGO , June 03, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will Read All » View HTML
Toggle Summary SAN DIEGO , May 06, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will Read All » View HTML
Toggle Summary FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 FT819 Enrollment Ongoing in Single- and Multi-dose Cohorts for R/R BCL in Landmark Study of Off-the-shelf, iPSC-derived Read All » View HTML
Toggle Summary SAN DIEGO , April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”)  (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company Read All » View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.